Slide 1: BONESUPPORT Q4 (2024) Report
BONESUPPORT Q4 (2024) Report February 25th , 2025 Emil Billbäck, CEO Håkan Johansson, CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: BONESUPPORT – Fourth quarter report 2024
BONESUPPORT – Fourth quarter report 2024 Q4 2024: • Net sales SEK 257 m, growth: +49% versus Q4 2023, (+48% in constant exchange rates, CER) • Operating result (before effects of incentive programs): SEK 78 m (SEK 11 m) • Reported EBIT: SEK 64 m (SEK -8 m) • Operating cash flow: SEK 73 m Full Year 2
Slide 4: Strong launch momentum for CERAMENT G in the US
Strong launch momentum for CERAMENT G in the US LTM Quarterly Sales per Segment 950 950 899 900 900 850 814 850 800 800 735 750 750 • CERAMENT G in the US reaching 700 655 700 SEK 154 m in the quarter 650 650 591 600 600 • Total antibiotic eluting CERAMENT Net Sales, SEK m Net Sales, SEK m 550 522 5
Slide 5: North America: Increasing geographic penetration and surgeon advocates
North America Increasing geographic penetration and surgeon advocates Q4 2024 • Sales of SEK 209 m, growth of 59% over Q4 2023 (growth of 58% in constant exchange rate, CER) Highlights in quarter • CERAMENT G sales of SEK 154 m • Good pick up of trauma surgeons starting to use CERAMENT G • Completed
Slide 6: EUROW: Market share gains fuels sales performance
EUROW Market share gains fuels sales performance Q4 2024 • Sales of SEK 48 m, growth of 16% vs Q4 2023, (growth of 17% in constant exchange rates, CER) • Political prioritization influencing British health care systems Highlights • EUROW sales Booster - Replicate successful Hybrid model in additiona
Slide 7: EUROW: Sales penetration acceleration and sales expansion
EUROW: Sales penetration acceleration and sales expansion • Strong continuous sales growth despite inertia in health care systems. Changing standard of care requires training and clinical support presence. • Increasing demand in under penetrated markets triggered by strong clinical studies, Key Opin
Slide 8: Improved survival rates using CERAMENT in Diabetic Foot Infections
Improved survival rates using CERAMENT in Diabetic Foot Infections Metaoy, S., Rusu, I. & Pillai, A. Adjuvant local antibiotic therapy in the management of diabetic foot osteomyelitis. Clin Diabetes Endocrinol 10, 51 (2024). 60 Study design 55.1% • Retrospective study on patients with diabetic foot
Slide 9: BONESUPPORT Q4 (2024) Report: Financial Report
BONESUPPORT Q4 (2024) Report Financial Report 9
Slide 10: Net Sales, MSEK
Q4 2024 net sales SEK 257.0 m Revenue vs PY Increase Decrease Total • NA: 59 percent reported growth. 300,0 58 percent growth in CER 76,8 6,9 0,5 257,0 250,0 • EUROW: 16 percent reported growth. 17 percent growth CER 200,0 Net Sales, MSEK 172,7 • Low impact from currency movements 150,0 100,0 50,0 0
Slide 11: Gross Margin
North America +59% EUROW +16% (+58% CER) (+17% CER) Net sales Net sales Q4-24 Q4-24 North America 2024 2023 EUROW 2024 2023 SEK m Q4 Q3 Q2 Q1 Q4 SEK m Q4 Q3 Q2 Q1 Q4 Net Sales 209,4 192,0 173,0 141,5 131,6 Net Sales 47,6 45,5 46,8 43,0 41,1 Gross profit 199,5 181,9 165,7 134,8 125,1 Gross profit 39,
Slide 12: R&D investments and temporary variances impacting
R&D investments and temporary variances impacting Key Figures 2024 2023 SEK m Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Selling expenses 71,2 65,5 67,6 59,7 59,6 53,5 55,0 49,0 Sales Commissions and fees 70,4 65,5 62,2 48,2 44,4 42,7 37,2 29,9 Research and Development expenses 21,8 19,7 20,3 14,1 17,6 12,5 14,6 12,5
Slide 13: 49% Sales growth and accelerated adjusted operating profit
49% Sales growth and accelerated adjusted operating profit Key Figures 2024 2023 SEK m Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Net Sales 257,0 237,5 219,8 184,4 172,7 158,2 140,4 119,7 Gross Margin (%) 92,6 92,9 92,3 92,6 91,8 92,1 91,3 90,5 Operating profit 64,2 41,0 28,7 32,3 -8,0 14,9 6,0 0,8 Adj. Operating prof
Slide 14: BONESUPPORT Q4 (2024) Report
BONESUPPORT Q4 (2024) Report • 49% sales growth (48% in CER) • SEK 78 m EBIT (before incentive cost) • Strong performance for CERAMENT G USA • Growing pool of breakthrough, standard-of- care altering clinical evidence • Sales growth above 40% (in CER) for 2025 14